Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group

G. Grignani; L. D'Ambrosio; Y. Pignochino; E. Palmerini; M. Zucchetti; P. Boccone; S. Aliberti; S. Stacchiotti; R. Bertulli; R. Piana; S. Miano; F. Tolomeo; G. Chiabotto; D. Sangiolo; A. Pisacane; A.P. Dei Tos; L. Novara; A. Bartolini; E. Marchesi; M. D'Incalci; A. Bardelli; P. Picci; S. Ferrari; M. Aglietta

doi:10.1016/S1470-2045(18)30438-8

Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group

G. Grignani, L. D'Ambrosio, Y. Pignochino, E. Palmerini, M. Zucchetti, P. Boccone, S. Aliberti, S. Stacchiotti, R. Bertulli, R. Piana, S. Miano, F. Tolomeo, G. Chiabotto, D. Sangiolo, A. Pisacane, A.P. Dei Tos, L. Novara, A. Bartolini, E. Marchesi, M. D'IncalciA. Bardelli, P. Picci, S. Ferrari, M. Aglietta

Research output: Contribution to journal › Article

Original language	Undefined/Unknown
Pages (from-to)	1360-1371
Number of pages	12
Journal	The Lancet Oncology
Volume	19
Issue number	10
DOIs	https://doi.org/10.1016/S1470-2045(18)30438-8
Publication status	Published - 2018

Cite this

Grignani, G., D'Ambrosio, L., Pignochino, Y., Palmerini, E., Zucchetti, M., Boccone, P., Aliberti, S., Stacchiotti, S., Bertulli, R., Piana, R., Miano, S., Tolomeo, F., Chiabotto, G., Sangiolo, D., Pisacane, A., Dei Tos, A. P., Novara, L., Bartolini, A., Marchesi, E., ... Aglietta, M. (2018). Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group. The Lancet Oncology, 19(10), 1360-1371. https://doi.org/10.1016/S1470-2045(18)30438-8

Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group. / Grignani, G.; D'Ambrosio, L.; Pignochino, Y.; Palmerini, E.; Zucchetti, M.; Boccone, P.; Aliberti, S.; Stacchiotti, S.; Bertulli, R.; Piana, R.; Miano, S.; Tolomeo, F.; Chiabotto, G.; Sangiolo, D.; Pisacane, A.; Dei Tos, A.P.; Novara, L.; Bartolini, A.; Marchesi, E.; D'Incalci, M.; Bardelli, A.; Picci, P.; Ferrari, S.; Aglietta, M.

In: The Lancet Oncology, Vol. 19, No. 10, 2018, p. 1360-1371.

Research output: Contribution to journal › Article

Grignani, G, D'Ambrosio, L, Pignochino, Y, Palmerini, E , Zucchetti, M, Boccone, P, Aliberti, S , Stacchiotti, S , Bertulli, R, Piana, R, Miano, S, Tolomeo, F, Chiabotto, G, Sangiolo, D , Pisacane, A, Dei Tos, AP, Novara, L, Bartolini, A, Marchesi, E, D'Incalci, M , Bardelli, A, Picci, P, Ferrari, S & Aglietta, M 2018, 'Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group', The Lancet Oncology, vol. 19, no. 10, pp. 1360-1371. https://doi.org/10.1016/S1470-2045(18)30438-8

Grignani, G. ; D'Ambrosio, L. ; Pignochino, Y. ; Palmerini, E. ; Zucchetti, M. ; Boccone, P. ; Aliberti, S. ; Stacchiotti, S. ; Bertulli, R. ; Piana, R. ; Miano, S. ; Tolomeo, F. ; Chiabotto, G. ; Sangiolo, D. ; Pisacane, A. ; Dei Tos, A.P. ; Novara, L. ; Bartolini, A. ; Marchesi, E. ; D'Incalci, M. ; Bardelli, A. ; Picci, P. ; Ferrari, S. ; Aglietta, M. / Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group. In: The Lancet Oncology. 2018 ; Vol. 19, No. 10. pp. 1360-1371.

@article{3cef366105864628aac5e43134e8996b,

title = "Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group",

author = "G. Grignani and L. D'Ambrosio and Y. Pignochino and E. Palmerini and M. Zucchetti and P. Boccone and S. Aliberti and S. Stacchiotti and R. Bertulli and R. Piana and S. Miano and F. Tolomeo and G. Chiabotto and D. Sangiolo and A. Pisacane and {Dei Tos}, A.P. and L. Novara and A. Bartolini and E. Marchesi and M. D'Incalci and A. Bardelli and P. Picci and S. Ferrari and M. Aglietta",

note = "cited By 2",

year = "2018",

doi = "10.1016/S1470-2045(18)30438-8",

language = "Non definita",

volume = "19",

pages = "1360--1371",

journal = "The Lancet Oncology",

issn = "1470-2045",

publisher = "Lancet Publishing Group",

number = "10",

}

TY - JOUR

T1 - Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group

AU - Grignani, G.

AU - D'Ambrosio, L.

AU - Pignochino, Y.

AU - Palmerini, E.

AU - Zucchetti, M.

AU - Boccone, P.

AU - Aliberti, S.

AU - Stacchiotti, S.

AU - Bertulli, R.

AU - Piana, R.

AU - Miano, S.

AU - Tolomeo, F.

AU - Chiabotto, G.

AU - Sangiolo, D.

AU - Pisacane, A.

AU - Dei Tos, A.P.

AU - Novara, L.

AU - Bartolini, A.

AU - Marchesi, E.

AU - D'Incalci, M.

AU - Bardelli, A.

AU - Picci, P.

AU - Ferrari, S.

AU - Aglietta, M.

N1 - cited By 2

PY - 2018

Y1 - 2018

U2 - 10.1016/S1470-2045(18)30438-8

DO - 10.1016/S1470-2045(18)30438-8

M3 - Articolo

VL - 19

SP - 1360

EP - 1371

JO - The Lancet Oncology

JF - The Lancet Oncology

SN - 1470-2045

IS - 10

ER -

Access to Document

10.1016/S1470-2045(18)30438-8

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85054775733&doi=10.1016%2fS1470-2045%2818%2930438-8&partnerID=40&md5=91d8b9b5c76f4b42ca66bc091076f7cc